Smoking in Egypt
Last week, the US approved the first schizophrenia medication in years with a novel mechanism of action. KarXT (sold as Cobenfy) targets muscarinic receptors in the brain, reducing dopamine release, a key factor in schizophrenia symptoms.
This milestone signals a new era in muscarinic drug development, according to molecular pharmacologist Andrew Tobin. Ancient Egyptians even used muscarinic receptor antagonists to treat airway diseases by inhaling smoke from an herb.
With modern drug design and a deeper understanding of these receptors, new medications offer hope for treating challenging neurological conditions like Alzheimer’s disease, drawing on ancient knowledge from the Middle East.
Comments
